INTRODUCTION
neural progenitor proteins such as nestin (8) , Sox2, Oct 4, and Musashi (4). Various stem cell markers are found in different ma-Malignant gliomas are the most common malignant primary intracranial tumors. Their incidence is 5.4/ lignant tumors. The CD133 tumor marker is specific and commonly used for CSCs of malignant gliomas (30). 100,000 (11) . Glioblastoma multiforme (GBM) (WHO IV) tumors are the most common highly invasive malig-Recent studies showed that biological behaviors of CD133 + were like the CSC subpopulation that confers nant gliomas. Their prognosis is still dismal even though aggressive surgery, radiotherapy, and chemotherapy are glioma radio-and chemoresistance (21,34). These stem cells may be the source of tumor recurrence after radia-used for treatment (40) . The median survival is only 12-15 months for GBM (22, 37) . It seems to be an incur-tion (25). Oka et al. (29) reported that CD133 + CSCs were identified in the peripheral brain regions adjacent able disease due to its highly infiltrative phenotype. There is growing evidence that GBM harbors small cell to the tumor. They were frequently localized around vascular structures (the vascular niche). Singh et al. (36) populations that may sustain tumor formation and growth. These cells are called cancer stem cells (CSCs) reported that CD133 + CSCs in GBM might be transplantable to xenograft tumors in SCID (severe combined (31, 32) . Cancer stem cells are not only found in leukemia, multiple myeloma, and breast cancer but also in immunodeficiency disease) mice brain, which recaptured the features of the original tumor regarding mor-GBM. The CSCs share many properties with normal stem cells including self-renewal and multipotency (14). phology lineage and marker expression, and generated both CD133 + and CD133 − cells. However, in the same They have also been shown to express various specific patient from whom the CD133 cells were obtained, the of tumor CSCs varied from 1.02% to 2.32% based on flow cytometric analysis. Singh et al. (36) reported less cells could not form neurospheres in culture medium and could not form tumor growth in SCID mice (18) . than 20% of CD133 + in total tumor mass, but wide ranging variations in the CD133 + cell ratio (0.1-50% in The CD133 CSC marker is analyzed by immunohistochemistry staining and Western blotting. The compo-GBM) were reported. Low-grade gliomas also contain glioma stem cells, but in relatively low numbers. Thon nent amount of CD133 + cells closely correlates with glioma malignancy. The quantities of CD133 + CSCs within et al. (38) also reported that the number of CD133 + cells quantitatively correlated with tumor grade. the tumor mass might show a clear quantitative correlation with glioma grading (WHO II, III, and IV). These NEOANGIOGENESIS IN CSCs findings support the concept of CD133 + CSC-dependent gliomagenesis (38) .
The CD133 + cells from gliomas of different grades might contribute to intratumoral neoangiogenesis. CD133 + ISOLATION AND IDENTIFICATION cells frequently accumulate within highly vascularized OF CSCs IN GLIOMAS regions, particularly in the case of GBM. Bao et al.
(2) The definition of CSCs must meet the following four reported evidence that the mutual influence of stem cells criteria: 1) generate clonally derived cells that form neuand endothelium account for neoangiogenesis. Thon et rospheres; 2) possess properties of cell renewal and proal. (38) also reported that CD133 + cells exhibit expresliferation; 3) differentiate and express typical CSC sion of endothelial progenitor and display a typical enmarkers of tumor cells; 4) generate tumors after in vivo dothelial "cobblestone" growing pattern. Vascular endotransplantation in animal models that resemble the origithelial growth factor (VEGF) promotes tumorigenesis nal donor tumors (39).
via angiogenesis (28). VEGF-repressing CSCs lead to CSCs of brain tumors were first identified in primary the massive expansion of vascular-rich GBM and tumorbrain tumors (e.g., GBM, medulloblastoma, pilocytic associated hemorrhage, thereby causing high morbidity. astrocytoma, and ganglioglioma). They formed clono-VEGF provides a vascular-rich tumor environment stem genic spheres (neurospheres) in serum-free culture mecell niche. dia containing epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). The CD133 marker is MICRO-RNA REGULATION OF CSCs a 120-kDa transmembrane cell-surface protein. In the Micro-RNAs (miRNAs) are a novel group of short course of enzymatic digestion of tumor tissue, an exces-RNAs, about 22 nucleotides in length, that regulate gene sively long incubation period easily damages CSCs and expression in a posttranscriptional manner by paring breaks the structure of cell-surface antigens. The CD133
with complementary nucleotide sequences in the 3′tumor marker can be also present in other tumors includuntranslatable region of target mRNA. The miRNAs ing prostate tumors and colon cancers. We may identify regulate cell functions, either oncogenesis or tumor sup-CSCs in cell culture by neurosphere formation with pospression, which influence cancer development and proitive CD133 + and nestin neural stem cell markers (42) .
gression. Recently, miRNA-7, miRNA-21, and miRNA-When the CSCs of brain tumor cells are transferred into 451 were found to be involved in regulation of brain the nude or SCID mice brain they may induce tumor differentiation (16) . MiRNA-451 may disperse neuformation (26). Singh et al. (36) demonstrated that as rospheres and inhibit the growth of GBM cells. MiRNAs few as 100 CD133 + cells derived from human GBM may drive CD133 + cells to differentiate and lose their could form GBM in SCID mice; however, the injection stem cell character. When the miRNA levels in CD133 + of 5 × 10 4 to 1 × 10 5 CD133 − cells did not. The CSCs cells are raised by transfection, there may be inhibition from gliomas are concentrated by cell sorting or magof cell growth and proliferation from loss of cell renewal netic columns using specific immunoreactivities. The potential. MiRNA-124 and miRNA-137 may also inhibit CSCs are thought to maintain their drug (Hoechst 33342 proliferation of GBM cells and induce differentiation of dye) efflux ability, which makes it possible to separate brain tumor stem cells (35). CSCs in unstained cell fractions (17). Kang et al. (19) reported radiation might increase CSCs from 2-3% ini-IMMUNE RESPONSE TO CSCs tially to 5-7% in recurrent tumor. Low-dose radiation The brain is not an immunologically exempt organ or hypoxic challenge might be used in the future for without elicitation of inflammation and immune reexperimental study to increase the concentration of sponse (1). According to tumor immunosurveillance the-CSCs in cell culture (20) . ory, tumor can be recognized and eliminated as a result THE COMPONENT AMOUNT of the natural antitumor immune response (9) . But in OF CSCs IN GLIOMAS tumor development, tumor cells may influence immunity either from the tumor environment, rendering a tu-CD133 + cell markers are positive in 60-70% of glioma tissue. Oka et al. (29) reported that the percentage mor invisible to the host immune system, or resistant to the antitumor response. Most cancers are composed of a cells also involve tumor stem cell proliferation. Knowing how to identify such tumor-specific signaling path-mixture of normal stem cell and CSCs. The antigenesis of normal stem cells and CSCs may be different. The ways and their inactivation mechanism will provide information on key targets for glioma treatment. In CSCs frequently escape the T-cell immune response. It is critical to fully characterize the immunological fea-comparison to CD133 − tumor cells, CD133 + CSCs have higher DNA repair capacity, which results in a selective tures of CSCs and to develop immunotherapeutic approaches to eliminate CSCs without excessive toxicity postirradiation increase in the CD133 + population (15). CSCs express multidrug resistance genes (e.g., ABCG2 to normal stem cells (41) . and BCRPI) that aide in the efflux of drugs and in the CHEMOSENSITIZER AND selective promotion of CSC survival (15) . The sonic RADIOSENSITIZER FOR CSCs hedgehog (shh) (10) and the Notch pathway are very important for brain development and for maintaining Liu et al. (24) reported that CD133 + CSCs play an important role in tumor resistance to chemotherapy. This cell "stemness." An shh pathway inhibitor, cyclopamine, depletes CSCs (3). In the Notch pathway, γ-secretase resistance is probably contributed to by CD133 + cells with greater expression of breast cancer resistance pro-inhibitors also decrease the CD133 + fraction (13) . Promoting the differentiation of stem cells to normal cells tein (BCRP1) and methyl-guanine methyltransferase (MGMT) as well as the antiapoptosis proteins and inhib-is another possible approach for CSC treatment. Piccirillo et al. (33) reported that bone morphogenetic protein itors of apoptosis protein families. Miqueli et al. (27) reported that the monoclonal antibodies for anti-epider-(BMP4) might reduce the CSCs in GBM by differentiating the CSCs to astrocytes. mal growth factor receptors can increase radiosensitization to GMB CSCs. Chang et al. (6) reported that the CONCLUSIONS mean survival rate of GBM with CD133 + mice treated with radiation was significantly improved by knock-Cancer stem cell investigation is a good starting point down of silencing information regulator (SirT1), a memfor controlling tumor growth and recurrence (23). Alber of the sirtuin family, which is an NAD-dependent though many differences in physiological behavior behistone deacetylase and essential mediator of longevity tween CSCs and normal stem cells are unclear, the more in normal cells. Ehtesham et al. (12) showed that cell we know about CSCs the more we can treat them effecsurface chemokine receptor (CCR4), a mediator of cantively. cer proliferation and invasion, was overexpressed in 
